Baidu
map

EUR J Cancer:基线癌胚抗原可以作为ramucirumab药物疗效的预测因子

2017-12-30 MedSci MedSci原创

Ramucirumab是一种完全的人源性单克隆抗体,主要用于治疗实体瘤。它是一种血管内皮生长因子受体(VEGFR)的抑制剂,可特异性地与受体结合并阻止细胞信号的传递。

Ramucirumab是一种完全的人源性单克隆抗体,主要用于治疗实体瘤。它是一种血管内皮生长因子受体(VEGFR)的抑制剂,可特异性地与受体结合并阻止细胞信号的传递。

一项III临床试验已经表明ramucirumab +(亚叶酸/5-氟尿嘧啶/伊立替康)FOLFIRI与安慰剂+ FOLFIRI相比能够显著改善经贝伐单抗和奥沙利铂化疗失败的转移性结直肠癌mCRC)患者的总生存期(OS)(风险比[HR] = 0.8495% CI  0.73-0.98P =0.022)。 研究者们对该项临床试验的回归性分析研究了癌胚抗原(CEA)亚组与有效性参数的关系。

Ramucirumab治疗延长了CEA<10ng/ml)亚组(HR=0.6895% CI 0.50-0.92P=0.013)和CEA>10ng/ml)亚组(HR=0.9095% CI 0.76-1.07P=0.233)的总生存期。然而,对于CEA<10ng/ml)亚组而言,ramucirumab相比于安慰剂,OS值更高,CEA<10ng/ml)亚组的中位OS3.6个月,CEA>10ng/ml)亚组的中位OS0.8个月。CEA水平与OS治疗效果的交互作用P值为0.088

尽管高、低CEA亚组的患者均能从ramucirumab治疗中获得较好的OSPFS数值,但CEA<10ng/mlmCRC患者亚组能够从ramucirumab治疗中获得更大益处。 

原始出处:

Yoshino, Takayuki, et al. "Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial." European Journal of Cancer 2017 78: 61-69. doi.org/10.1016/j.ejca.

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2007180, encodeId=9718200e18070, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat May 26 09:34:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911931, encodeId=0aa919119318f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 17 06:34:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310660, encodeId=490e131066056, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419686, encodeId=da0b1419686ec, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460335, encodeId=335f1460335a0, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623270, encodeId=d7f616232e046, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2007180, encodeId=9718200e18070, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat May 26 09:34:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911931, encodeId=0aa919119318f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 17 06:34:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310660, encodeId=490e131066056, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419686, encodeId=da0b1419686ec, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460335, encodeId=335f1460335a0, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623270, encodeId=d7f616232e046, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=)]
    2018-09-17 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=2007180, encodeId=9718200e18070, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat May 26 09:34:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911931, encodeId=0aa919119318f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 17 06:34:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310660, encodeId=490e131066056, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419686, encodeId=da0b1419686ec, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460335, encodeId=335f1460335a0, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623270, encodeId=d7f616232e046, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2007180, encodeId=9718200e18070, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat May 26 09:34:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911931, encodeId=0aa919119318f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 17 06:34:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310660, encodeId=490e131066056, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419686, encodeId=da0b1419686ec, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460335, encodeId=335f1460335a0, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623270, encodeId=d7f616232e046, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2007180, encodeId=9718200e18070, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat May 26 09:34:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911931, encodeId=0aa919119318f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 17 06:34:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310660, encodeId=490e131066056, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419686, encodeId=da0b1419686ec, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460335, encodeId=335f1460335a0, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623270, encodeId=d7f616232e046, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2007180, encodeId=9718200e18070, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sat May 26 09:34:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911931, encodeId=0aa919119318f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Sep 17 06:34:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310660, encodeId=490e131066056, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419686, encodeId=da0b1419686ec, content=<a href='/topic/show?id=8af1e1542d2' target=_blank style='color:#2F92EE;'>#癌胚抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71542, encryptionId=8af1e1542d2, topicName=癌胚抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d123523167, createdName=lifangping, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460335, encodeId=335f1460335a0, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623270, encodeId=d7f616232e046, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Jan 01 13:34:00 CST 2018, time=2018-01-01, status=1, ipAttribution=)]

相关资讯

ASCO 2014:Ramucirumab+多西他赛延长NSCLC生存期 (REVEL研究)

摘要号:LBA8006 IV期非小细胞肺癌(NSCLC)患者的REVEL III期研究的结果表明,一种新的抗-血管生成药物,ramucirumab,和标准多西他赛化疗的联合方案可以延长初始化疗后复发患者的总生存期,并与多西他赛+安慰剂方案进行比较。在ramucirumab组的中位总生存期是10.5个月,与安慰剂组的9.1个月相对比。 “这是大约十年,在二线方案中首个用来提高患者预后的治

Lancet:Ramucirumab二线治疗没有显著提高中晚期肝癌患者的生存率

    背景  VEGF和VEGF受体-2介导的血管生成促进肝癌发病。 Ramucirumab是重组IgG1单克隆抗体,是血管内皮生长因子受体-2拮抗剂。该研究的目的是评估以索拉非尼一线治疗晚期肝细胞癌后用ramucirumab治疗的安全性和有效性。    方法  在这项随机,安慰剂对照,双盲,多中心,3期临床试验(REACH)中,患者来

J Gastroenterol:Ramucirumab治疗日本晚期肝癌患者疗效如何?

Ramucirumab是一种完全的人源性单克隆抗体,主要用于治疗实体瘤。它是一种血管内皮生长因子2(VEGFR)的抑制剂,可特异性地与受体结合并阻止受体活化。 EACH试验对晚期肝细胞癌患者的二线治疗ramucirumab进行了评估。在意向性治疗人群(n = 565)中没有发现总生存期(OS)的显著改善,不过对于α-甲胎蛋白(AFP)升高(≥400 ng/mL)患者,发现OS有改善。本研究对

ASCO 2014:Ramucirumab+FOLFOX作为晚期胃/食管癌一线治疗?

Ramucirumab(RAM),一种抗-VEGFR2单克隆抗体,在3项2期试验中可提高之前已治疗过的胃/胃食管交界处(GEJ)腺癌患者的总生存期(OS)。本项研究是将RAM作为晚期胃癌或者食管腺癌(GE-AC)一线治疗的第一次评估。 未经处理的转移性或者局部晚期不能手术切除的GE-AC(PS≤1)患者,按照1:1随机分配到mFOLFOX+RAM(8mg/kg IV)组和安慰剂组(PL),q

Lancet Oncology:Ramucirumab+紫杉醇治疗进展期胃癌疗效显著(RAINBOW Ⅲ期试验)

背景: VEGFR-2在胃癌发病机制及进展过程中发挥重要作用。Ramucirumab是一种抗VEGFR2单克隆抗体,本次研究试验目的是评价Ramucirumab联合紫杉醇对比安慰剂联合紫杉醇二线治疗进展期胃癌的疗效。 研究方法: RAINBOW研究为全球多中心随机双盲对照3期临床试验。入选标准:18岁及以上的进展期胃或胃食管结合部腺癌患者,一线氟尿嘧啶类+铂类药物治疗4个月内进展

Br J Cancer:Ramucirumab疗效相关生物标志物研究

抑制血管生成是癌症治疗过程中的重要策略和目标之一。Ramucirumab是靶向血管内皮生长因子受体2(VEGFR2)的人类IgG1单克隆抗体,能抑制VEGF-A、-C、-D结合以及内皮细胞增殖。 我们对REGARD 3期试验中的转移性胃癌/胃食管交界处癌患者进行了回顾性研究,分析肿瘤(HER2, VEGFR2)和血清(VEGF-C and -D, 水溶性 (s) VEGFR1 and 3)中

Baidu
map
Baidu
map
Baidu
map